Distinctive shift technology
HYDRASHIFT daratumumab and HYDRASHIFT isatuximab avoid daratumumab or isatuximab interference on HYDRAGEL IF tests.
Therapeutic monoclonal antibody (mAb) inclusion in Multiple Myeloma treatment regimens offer patients significant improvements in clinical outcomes. daratumumab and isatuximab are human mAb targeting CD38 used in Multiple Myeloma treatment regimens.
HYDRASHIFT avoids therapeutic mAb interference on Immunofixation interpretation assays.
HYDRASHIFT daratumumab and HYDRASHIFT isatuximab avoid daratumumab or isatuximab interference on HYDRAGEL IF tests.
HYDRASHIFT reduce the risk of incorrect IF interpretation to improve therapy monitoring.
Fully integrated into IF protocol without sample pre-treatment for a standardized process compliant to IMWG guidelines.
Process compliant to IMWG guidelines to assess response to treatment in patient with Multiple Myeloma.
HYDRASHIFT is an immunofixation technique performed on HYDRAGEL IF 2/4 gel that works by creating immune complexes between therapeutic monoclonal antibodies (daratumumab or isatuximab) and specific anti-mAB antisera. The resulting complexes shift migration to the alpha region, facilitating distinction from patient M-proteins.
This complex is visible in the IgG and kappa immunofixation tracks. A negative HYDRASHIFT result demonstrates the absence of endogenous M-protein.
Serum
Sensitivity
The limit of immune complex visualized is 0.3 g/L.
Large menu with high quality results on gel electrophoresis.
Cette section contient des informations destinées à une large diffusion et peut donc comporter des détails sur des produits ou des informations qui ne sont pas disponibles ou valables dans votre pays. Veuillez contacter votre représentant Sebia local. Informations destinées aux professionnels de santé. Lisez attentivement les instructions figurant dans les notices des réactifs et les manuels d'utilisation des instruments.